Why big pharma has abandoned antibiotics
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Nature 586, S50-S52 (2020)
This article is part of Nature Outlook: Antimicrobial resistance, an editorially independent supplement produced with the financial support of third parties. About this content.
Towse, A. et al. Health Policy 121, 1025–1030 (2017).
Kuo, Y.-T. et al. Lancet Gastroenterol. Hepatol. 2, 707–715 (2017).
Roope, L. S. J. et al. Science 364, eaau4679 (2019).
Sharma, P. & Towse, A. New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options (OHE, 2014).
Projan, S. J. et al. Curr. Opin. Microbiol. 6, 427–430 (2003).
Stokes, J. M. et al. Cell 180, 688–702 (2020).
Enne, V. I., Livermore, D. M., Stephens, P. & Hall, L. M. C. Lancet 357, 1325–1328 (2001).
Sundqvist, M. et al. J. Antimicrob. Chemotherpy 65, 350– 360 (2010).
Schneider, M., Harrison, N. R., Daniel, G. W. & McClellan, M. B. Delinking US Antibiotic Payments through a Subscription Model in Medicare (Duke-Margolis Center for Health Policy, 2020).